Only two companies completed initial public offerings this past week and both ended the week about 1% from the IPO price. Ear disease biotech Otonomy (OTIC) priced at the high end of its range and gained 7% on the first day, but settled to just 1% above...read more
Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, raised $100 million in an upsized IPO by offering 6.3 million shares at $16.00, at the high end of the range of $14.00 to $16.00. The company originally planned to offer 5.3...read more
There are four initial public offerings on the calendar this week as the IPO market slows down during an annual three-week pause. Turbulence in broader indices has pressured IPOs; about one third of expected IPOs were delayed or postponed in each of the past two...read more
Auris Medical, a biotech developing treatments for tinnitus and other inner ear disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Zug, Switzerland-based company now plans to raise $56 million by offering 9.4 million shares at a price...read more
US IPO Pricing Recap: Two deals trade flat before a two-week break in the IPO market
Only two companies completed initial public offerings this past week and both ended the week about 1% from the IPO price. Ear disease biotech Otonomy (OTIC) priced at the high end of its range and gained 7% on the first day, but settled to just 1% above...read more
Otonomy prices upsized IPO at $16, the high end of the range
Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, raised $100 million in an upsized IPO by offering 6.3 million shares at $16.00, at the high end of the range of $14.00 to $16.00. The company originally planned to offer 5.3...read more
4 US IPOs planned for the week of Aug 11
There are four initial public offerings on the calendar this week as the IPO market slows down during an annual three-week pause. Turbulence in broader indices has pressured IPOs; about one third of expected IPOs were delayed or postponed in each of the past two...read more
Auris Medical slashes proposed price to $6, increases insider buying; market cap drops 40%
Auris Medical, a biotech developing treatments for tinnitus and other inner ear disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Zug, Switzerland-based company now plans to raise $56 million by offering 9.4 million shares at a price...read more